Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Coghill

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
CNS Drugs|May 24, 2018
Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity DisorderTobias Banaschewski, Mats Johnson, Peter Nagy, et al.
Journal of Child and Adolescent Psychopharmacology|April 4, 2019
Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No PharmacotherapyGary Schneider, Tobias Banaschewski, Brian L Feldman, et al.
CNS Drugs|July 21, 2014
Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorderRalf W Dittmann, Esther Cardo, Peter Nagy, et al.
Neuroscience Letters|July 7, 2009
Replication of an association of a promoter polymorphism of the dopamine transporter gene and Attention Deficit Hyperactivity DisorderChristopher Doyle, Keeley Brookes, Jennifer Simpson, et al.
European Child & Adolescent Psychiatry|May 28, 2013
Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trialDavid R Coghill, Tobias Banaschewski, Michel Lecendreux, et al.
Pediatrics|February 5, 2008
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorderMark E Bangs, Philip Hazell, Marina Danckaerts, et al.
BMJ Open|November 23, 2022
Examining the pharmacological and psychological treatment of child and adolescent ADHD in Australia: Protocol for a retrospective cohort study using linked national registry dataDaniel P Sullivan, Leanne Payne, Kelsie A Boulton, et al.
CNS Drugs|June 27, 2013
A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescentsCésar Soutullo, Tobias Banaschewski, Michel Lecendreux, et al.
CNS Drugs|June 13, 2016
The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of ResearchVictoria A Reed, Jan K Buitelaar, Ernie Anand, et al.
BMJ Open|September 1, 2018
Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trialNatalie A Pride, Belinda Barton, Paul Hutchins, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
CNS Drugs|May 24, 2018
Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity DisorderTobias Banaschewski, Mats Johnson, Peter Nagy, et al.
Journal of Child and Adolescent Psychopharmacology|April 4, 2019
Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No PharmacotherapyGary Schneider, Tobias Banaschewski, Brian L Feldman, et al.
CNS Drugs|July 21, 2014
Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorderRalf W Dittmann, Esther Cardo, Peter Nagy, et al.
Neuroscience Letters|July 7, 2009
Replication of an association of a promoter polymorphism of the dopamine transporter gene and Attention Deficit Hyperactivity DisorderChristopher Doyle, Keeley Brookes, Jennifer Simpson, et al.
European Child & Adolescent Psychiatry|May 28, 2013
Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trialDavid R Coghill, Tobias Banaschewski, Michel Lecendreux, et al.
Pediatrics|February 5, 2008
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorderMark E Bangs, Philip Hazell, Marina Danckaerts, et al.
BMJ Open|November 23, 2022
Examining the pharmacological and psychological treatment of child and adolescent ADHD in Australia: Protocol for a retrospective cohort study using linked national registry dataDaniel P Sullivan, Leanne Payne, Kelsie A Boulton, et al.
CNS Drugs|June 27, 2013
A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescentsCésar Soutullo, Tobias Banaschewski, Michel Lecendreux, et al.
CNS Drugs|June 13, 2016
The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of ResearchVictoria A Reed, Jan K Buitelaar, Ernie Anand, et al.
BMJ Open|September 1, 2018
Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trialNatalie A Pride, Belinda Barton, Paul Hutchins, et al.
Pageof 4